Posted at 17:35h
in
Cannabis
Editor's note: Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects.
Do not use Cannabis products including edibles and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products.
[caption id="attachment_70032" align="aligncenter" width="500"]
Freepik image[/caption]
The human body is a complex network of systems working harmoniously to maintain balance and health. One of the lesser-known but critically important systems is the
endocannabinoid system (ECS). This intricate system plays a vital role in regulating a variety of physiological processes, including mood, pain sensation, appetite, and immune response. Central to the ECS are cannabinoids: both those produced naturally within the body and those introduced from external sources like cannabis.
Understanding how cannabinoids interact with the endocannabinoid system is key to unlocking their therapeutic potential and appreciating their impact on human health.
What is the Endocannabinoid System?
The endocannabinoid system is a biological network found in all vertebrates, including humans. It consists primarily of three components:
- Endocannabinoids
- Cannabinoid receptors
- Enzymes that synthesize and degrade endocannabinoids
Discovered in the early 1990s, the ECS has since been recognized as a crucial regulator of homeostasis—the body’s internal balance.
Endocannabinoids are naturally occurring lipid-based neurotransmitters, the most well-known being
anandamide and 2-arachidonoylglycerol (2-AG). These molecules bind to cannabinoid receptors, which are located throughout the body, including the brain, immune cells, organs, and connective tissues. The two primary
receptors are CB1 and CB2, each with distinct functions and locations.
CB1 receptors are predominantly found in the central nervous system, influencing memory, pain, and motor control, while CB2 receptors are mostly present in the peripheral nervous system and immune cells, modulating inflammation and immune responses.
Dr. Casale[/caption]
Thomas B. Casale, M.D.
Professor of Medicine and Pediatrics
Chief of Clinical and Translational Research
Division of Allergy and Immunology
USF Health Morsani College of Medicine
University of South Florida
Tampa, Florida
MedicalResearch.com: What is the background for this study?
Response: The data leading to FDA approval of neffy came from extensive pharmacokinetic and pharmacodynamic studies. As with previous epinephrine delivery devices, the FDA asked for data showing that after delivery of neffy the epinephrine blood levels and expected changes in pulse and blood pressure were similar to those achieved with injectable formulations of epinephrine. neffy performed as expected with blood levels of epinephrine bracketed by those achieved with EpiPen and a needle and syringe along with increases in pulse and blood pressure compatible with the epinephrine levels measured.
Additionally, clinicians are interested in whether neffy would perform similarly in real clinical situations. The data from the neffy experience program provides real-world assurance that neffy can effectively treat acute allergic reactions. Given the large number of patients and the similar findings to those achieved with injectable epinephrine in previous studies, the data should provide assurance that neffy can be an effective substitute for injectable epinephrine in patients that desire a needle-free option.
Maria Tan[/caption]
MedicalResearch.com:
Maria Y. Tian, MBS
Department of Medical Education
Geisinger College of Health Sciences
Scranton, Pennsylvania
MedicalResearch.com: What is the background for this study?
Response: Schizophrenia-spectrum disorders are severe, disabling conditions that are associated with substantial economic burden. Approximately one-third of patients have treatment-resistant schizophrenia, which clozapine is the only evidence-based therapy for. Clozapine also provides unique benefits, including reduced suicide risk, aggression, and all-cause mortality. Despite this, it has historically been underutilized due to concerns over adverse effects, required blood monitoring, patient adherence, and limited clinician training. Previous research in Medicaid populations had demonstrated marked state-level variation in use, but little was known about prescribing trends in the U.S. Medicare system, which covers nearly half of individuals with schizophrenia. This study analyzed Medicare Part D data from 2015–2020 to assess national and regional trends in clozapine prescribing and to identify states with significantly different prescribing patterns.
Dr. Donofry[/caption]
Shannon D. Donofry Ph.D.
Behavioral Scientist
B.A.Sc. in psychology/neuroscience
University of Pittsburgh-Pittsburgh Campus;
Ph.D, University of Pittsburgh-Pittsburgh Campus
[caption id="attachment_70207" align="alignleft" width="125"]
Dr. Rancaño[/caption]
Katherine M. Rancaño, Ph.D
Associate Policy Researcher
RAND
MedicalResearch.com: What is the background for this study?
Response: GLP-1 medications were first used to help people with diabetes manage their blood sugar. Lately, they’ve become popular for helping people lose weight, too. Because of this, a lot more people have started using them. In our study, we asked over 8,000 adults from across the country about their use of GLP-1 medications and any side effects they had.
Dr. Dunbar[/caption]
MedicalResearch.com Interview with:
Michael S. Dunbar, PhD
L. Levi[/caption]
Liran Levi, PhD student
Faculty of Medicine at Hebrew University
MedicalResearch.com: What is the background for this study?
Response: Motivated behavior is driven by a group of brain regions called collectively the reward system. This neural system is at the heart of every decision we make about our actions - it integrates information about the world and decides whether to perform a behavior or not based on the predicted reward/benefit. The key molecule in this process is dopamine - whenever we perform a behavior that provides a reward dopamine is released in the reward system and reinforces this behavior. Drugs of abuse exploit this system - they cause abnormally high levels of dopamine, and thus force the reward system to seek drugs constantly, even after prolonged withdrawal. From a neurobiological perspective, that is how we view substance dependence - the reward system drives people to seek for the reward.
